Correspondence with MAFF relating to claims to nuclear transfer intellectual property
- Reference:GB 237 Coll-1644/2/3
- Dates of Creation:1995-1999
- Physical Description:2 Files
Scope and Content
Contains correspondence with MAFF relating to the intellectual property of Roslin's nuclear transfer work in light of 'Dolly' patents and the establishment of Roslin BioMed and its acquisition by Geron.
Administrative / Biographical History
Following the birth of Dolly the sheep in 1996, Roslin Institute began to explore potential commercial applications of the nuclear transfer technique which had been used to produce her: particularly with the establishment of Roslin Bio-Med during 1997. MAFF claimed to have intellectual property rights over nuclear transfer, with Roslin's counter-argument being that the critical experiment which produced Dolly was funded from Roslin's own reserves. Ultimately, it was agreed that intellectual property rights would be halved between MAFF and Roslin.
Access Information
Researchers will need to fill out a Data Protection undertaking form to access this material.
Subjects
Corporate Names